Arcadia Biosciences Inc.

3.19
0.20 (6.77%)
At close: Apr 24, 2025, 3:59 PM
3.25
1.88%
After-hours: Apr 24, 2025, 07:15 PM EDT

Arcadia Biosciences Statistics

Share Statistics

Arcadia Biosciences has 1.37M shares outstanding. The number of shares has increased by 0.31% in one year.

Shares Outstanding 1.37M
Shares Change (YoY) 0.31%
Shares Change (QoQ) 0.15%
Owned by Institutions (%) 99.99%
Shares Floating 1.36M
Failed to Deliver (FTD) Shares 61
FTD / Avg. Volume 1.07%

Short Selling Information

The latest short interest is 13.36K, so 0.98% of the outstanding shares have been sold short.

Short Interest 13.36K
Short % of Shares Out 0.98%
Short % of Float 0.98%
Short Ratio (days to cover) 2.82

Valuation Ratios

The PE ratio is -1.15 and the forward PE ratio is -1.36. Arcadia Biosciences's PEG ratio is 0.02.

PE Ratio -1.15
Forward PE -1.36
PS Ratio 1.6
Forward PS 0.6
PB Ratio 1.3
P/FCF Ratio -0.84
PEG Ratio 0.02
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Arcadia Biosciences.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.61, with a Debt / Equity ratio of 0.02.

Current Ratio 3.61
Quick Ratio 3.25
Debt / Equity 0.02
Debt / EBITDA -0.02
Debt / FCF -0.02
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $560.56K
Profits Per Employee $-782K
Employee Count 9
Asset Turnover 0.37
Inventory Turnover 3.28

Taxes

Income Tax 8K
Effective Tax Rate -0.19%

Stock Price Statistics

The stock price has increased by 67.89% in the last 52 weeks. The beta is 0.78, so Arcadia Biosciences's price volatility has been higher than the market average.

Beta 0.78
52-Week Price Change 67.89%
50-Day Moving Average 3.42
200-Day Moving Average 3.71
Relative Strength Index (RSI) 53.01
Average Volume (20 Days) 5.72K

Income Statement

In the last 12 months, Arcadia Biosciences had revenue of 5.04M and earned -7.04M in profits. Earnings per share was -5.16.

Revenue 5.04M
Gross Profit 2.08M
Operating Income -3.65M
Net Income -7.04M
EBITDA -7.5M
EBIT -7.61M
Earnings Per Share (EPS) -5.16
Full Income Statement

Balance Sheet

The company has 4.24M in cash and 155K in debt, giving a net cash position of 4.09M.

Cash & Cash Equivalents 4.24M
Total Debt 155K
Net Cash 4.09M
Retained Earnings -278.88M
Total Assets 13.52M
Working Capital 6.68M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -9.63M and capital expenditures -16K, giving a free cash flow of -9.64M.

Operating Cash Flow -9.63M
Capital Expenditures -16K
Free Cash Flow -9.64M
FCF Per Share -7.07
Full Cash Flow Statement

Margins

Gross margin is 41.27%, with operating and profit margins of -72.31% and -139.5%.

Gross Margin 41.27%
Operating Margin -72.31%
Pretax Margin -85.41%
Profit Margin -139.5%
EBITDA Margin -148.64%
EBIT Margin -72.31%
FCF Margin -191.14%

Dividends & Yields

RKDA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for RKDA is $6, which is 88.1% higher than the current price. The consensus rating is "Buy".

Price Target $6
Price Target Difference 88.1%
Analyst Consensus Buy
Analyst Count 1
Stock Forecasts

Stock Splits

The last stock split was on Mar 1, 2023. It was a backward split with a ratio of 1:40.

Last Split Date Mar 1, 2023
Split Type backward
Split Ratio 1:40

Scores

Altman Z-Score -29.82
Piotroski F-Score 1